LSRM Stock Overview A clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
CEL-SCI Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for CEL-SCI Historical stock prices Current Share Price US$0.68 52 Week High US$2.82 52 Week Low US$0.46 Beta 0.57 1 Month Change 21.14% 3 Month Change -27.98% 1 Year Change -71.58% 3 Year Change -90.47% 5 Year Change -91.03% Change since IPO -99.24%
Recent News & Updates
CEL-SCI Corporation Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study Dec 13
CEL-SCI Corporation Names Patricia B. Prichep as Chief Financial Officer Nov 17
CEL-SCI Corporation Names Patricia B. Prichep as Chief Financial Officer Nov 16
U.S. FDA and CEL-SCI Corporation Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence First Quarter 2025 Nov 08
CEL-SCI Corporation Reports New Data from Its Concluded Phase 3 Study of Multikine® (Leukocyte Interleukin, Injection) Sep 16
The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI Corporation A Pediatric Waiver, Bringing Multikine One Step Closer to Future Marketing Clearance Sep 05 See more updates
CEL-SCI Corporation Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study Dec 13
CEL-SCI Corporation Names Patricia B. Prichep as Chief Financial Officer Nov 17
CEL-SCI Corporation Names Patricia B. Prichep as Chief Financial Officer Nov 16
U.S. FDA and CEL-SCI Corporation Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence First Quarter 2025 Nov 08
CEL-SCI Corporation Reports New Data from Its Concluded Phase 3 Study of Multikine® (Leukocyte Interleukin, Injection) Sep 16
The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI Corporation A Pediatric Waiver, Bringing Multikine One Step Closer to Future Marketing Clearance Sep 05 CEL-SCI Corporation has completed a Follow-on Equity Offering in the amount of $10.7737 million. Jul 30
New major risk - Financial position Jul 29 CEL-SCI Corporation has filed a Follow-on Equity Offering in the amount of $10.845 million. Jul 27
CEL-SCI Corporation Announces Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Jul 26
CEL-SCI Corporation Appoints Robert Watson as Chairperson of the Board Jul 08
CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell 3000E Value Index Jul 03
New major risk - Financial position May 17 CEL-SCI Corporation Announces Significantly Positive Outcome from its Recent Meeting with U.S. Food and Drug Administration Regarding Path to Approval for its First-Line Investigational Cancer Immunotherapy Multikine
Less than half of directors are independent Apr 30
No longer forecast to breakeven Apr 15
New minor risk - Market cap size Mar 24
CEL-SCI Corporation, Annual General Meeting, Apr 19, 2024 Mar 08 CEL-SCI Corporation has filed a Follow-on Equity Offering in the amount of $7.75 million. Feb 09
CEL-SCI Corporation has completed a Follow-on Equity Offering in the amount of $4.98 million. Nov 21 CEL-SCI Corporation has filed a Follow-on Equity Offering in the amount of $4.98 million. Nov 18
CEL-SCI Corporation has filed a Follow-on Equity Offering in the amount of $4.98 million. Nov 17
CEL-Sci Corporation Releases Video Detailing Recent Phase 3 Findings & Its Plans to Seek Immediate Regulatory Approvals Oct 26
CEL-SCI Presents the Data for the First Time at the European Society for Medical Oncology Congress in Spain Oct 24
Cel-Sci Files Request with the Uk's Mhra Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer Oct 06
Cel-Sci Submits Scientific Advice Filing to European Medicines Agency (Ema) for Multikine in the Treatment of Head & Neck Cancer Sep 27
CEL-SCI Corporation Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine’s Increased Efficacy and Points to Potential for Combination with Checkpoint Inhibitors for Head & Neck Cancer Jul 13
CEL-SCI Corporation to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer--New Patent to Be Filed Jun 24
CEL-SCI Corporation to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer--New Patent to Be Filed Jun 23
CEL-SCI Corporation Announces Latest Results from Its Pivotal Phase 3 Study of Multikine May 16
No longer forecast to breakeven Feb 28
Forecast breakeven date moved forward to 2023 Feb 19
Forecast breakeven date pushed back to 2024 Dec 30
Forecast breakeven date pushed back to 2024 Aug 25
CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Aug 20
CEL-SCI Corporation Appoints Gail Naughton to its Board of Directors Aug 09 CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell 3000E Growth Index
CEL-SCI Corporation, Annual General Meeting, Jun 13, 2022 May 02
Insufficient new directors Apr 27
Chief Scientific Officer recently sold €145k worth of stock Oct 22
Forecast breakeven pushed back to 2023 Jun 30
Insider recently sold €203k worth of stock Apr 24
New 90-day high: €12.71 Jan 27
Full year 2020 earnings released: US$0.82 loss per share Dec 31
Revenue misses expectations Dec 31
CEL-SCI’s LEAPS Peptides Demonstrate Clear Survival Benefit as A Treatment for COVID-19 in Preclinical Studies Dec 02
Insider recently sold €108k worth of stock Nov 17
New 90-day high: €12.79 Oct 14
Third quarter earnings released Aug 11
New 90-day low - €10.80 Jul 24 Shareholder Returns LSRM DE Biotechs DE Market 7D 8.9% -2.6% -2.0% 1Y -71.6% -13.2% 6.8%
See full shareholder returns
Return vs Market: LSRM underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is LSRM's price volatile compared to industry and market? LSRM volatility LSRM Average Weekly Movement 15.6% Biotechs Industry Average Movement 6.9% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.4% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: LSRM's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: LSRM's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Founded Employees CEO Website 1983 n/a Geert Kersten cel-sci.com
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company’s lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer.
Show more CEL-SCI Corporation Fundamentals Summary How do CEL-SCI's earnings and revenue compare to its market cap? LSRM fundamental statistics Market cap €44.75m Earnings (TTM ) -€27.96m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) LSRM income statement (TTM ) Revenue US$0 Cost of Revenue US$18.95m Gross Profit -US$18.95m Other Expenses US$10.15m Earnings -US$29.10m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 16:33 End of Day Share Price 2024/12/23 00:00 Earnings 2024/06/30 Annual Earnings 2023/09/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources CEL-SCI Corporation is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Andrew Fein Chardan Capital Markets, LLC Christian Orquera First Berlin Equity Research GmbH Vernon Bernardino H.C. Wainwright & Co.
Show 4 more analysts 
